An interventional study of Ventilator weaning first and ECMO weaning first in Acute Respiratory Distress Syndrome, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 45th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18+
BioAegis Therapeutics Inc. · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 23 wk–31 wk
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2003; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 40 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 114 across the 26 interventional studies, 132 across the 21 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 7 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05947955BioAegis Therapeutics Inc.Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional clinical trial is to compare patients who undergo ECMO therapy for treatment of acute respiratory distress syndrome (ARDS) and a randomized into one of two possible weaning strategy groups.
Group 1: Weaning from ventilator occurs before ECMO weaning.
Group 2: Weaning from ECMO occurs before weaning from ventilator.
This study investigates which one of these strategies is more indulgent for the lung, and leads to less inflammation and therefore less potential side effects and an overall more favourable clinical course.
As a primary criterion, measure of IL-6 in blood samples will beused. As secondary criterions, SOFA score at various time points, ventilation pressures, lung injury score (LIS), length of stay in the intensive care unit, and ventilator-associated pneumonia as well as levels of inflammatory cells and cytokines in both blood samples and bronchoalveolar lavage at different time points will be determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Ventilator weaning first
Procedure: ECMO weaning first
Ventilator weaning initiated and completed before start of ECMO weaning.
ECMO weaning initiated and completed before start of ventilator weaning.
IL-6 concentration (blood samples)
Daily control of above mentioned parameter.
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
SOFA-Score
Sequential organ failure assessement score evaluated at days 1-14, 28, and 60.
Time frame: For the duration of the ICU stay, or a maximum of 60 days at indicated time points as described above..
Ventilation pressures
Pressures applied to the lung during artificial ventilation
Time frame: For the duration of the artificial ventilation, or a maximum of 60 days.
Murray Lung Injury Score (LIS)
Assessement of severity of lung damage by the established Lung Injury Score by Murray (Min Value is 0, healthy and Max Value is 20, severly diseased)
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
Length of stay in the intensive care unit
Length of stay in the intensive care unit.
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
Ventilator-associated pneumonia
Occurence/incidence of ventilator-associated pneumonia.
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
Cytokines and inflammatory cells in blood samples (IL-1beta, Il-10 and TNF-alpha)
Collection of blood samples at various times points for further analysis.
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
Cytokines and inflammatory cells in bronchoalveolar lavage (IL-1beta, Il-10 and TNF-alpha)
Collection of bronchoalveolar lavage samples at various times points for further analysis.
Time frame: For the duration of the ICU stay, or a maximum of 60 days.
Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 36 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 36 months is above that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
University Hospital Tuebingen →